Top
image credit: Adobe Stock

A new generation of biotech leaders is emerging. Can they change how drug startups are built?

February 14, 2023

Category:

Kevin Parker is an expert in genomics, immuno-oncology and computational biology. A Ph.D. scientist from Stanford University, he has helped author research in prestigious journals like Science, Nature Medicine and Cell.

But two years ago, when Parker was working with colleagues on an idea for a new biotechnology company, he found himself in unfamiliar territory. Skilled at navigating thorny scientific challenges, Parker was stumped by the process of building a startup.

Read More on Biopharma Dive